How Did Integral Diagnostics (ASX:IDX) Perform in FY26 After Its Imaging Network Expansion?

Aditi Sarkar

02 November 2026 06:10 PM AEDT

How Did Integral Diagnostics (ASX:IDX) Perform in FY26 After Its Imaging Network Expansion?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 Revenue and other income reached AUD 788.7 million, up 25.6% year on year.
Operating free Cash Flow was AUD 106.4 million, while net Debt to operating EBITDA was 2.3 times.
The expanded imaging network brings integration, staffing and equipment requirements.

Integral Diagnostics Limited provides diagnostic imaging services through radiology clinics across Australia and New Zealand, serving patients and medical referrers. Its network includes MRI, CT, ultrasound and other medical imaging capabilities. The company also operates teleradiology services. Integral Diagnostics (ASX:IDX) shares closed at AUD 1.745 on 2 November 2026. The latest financial year brought a larger consolidated business, new clinic openings and integration expenditure associated with the expanded imaging network.

FY26 Earnings and cash flow

In its 25 August 2026 results, Integral Diagnostics (ASX:IDX) reported revenue and other income of AUD 788.7 million for the year ended 30 June 2026, an increase of 25.6% year on year. Operating EBITDA reached AUD 164.8 million, up 30.3%, with the operating EBITDA Margin at 20.9%. Operating net profit after tax was AUD 47.4 million, while statutory net profit after tax was AUD 22.0 million. The difference reflected transaction, integration, restructuring and related adjustments disclosed in the results. Operating free cash flow totalled AUD 106.4 million, up 30.7%.

These measures distinguish recurring operating performance from statutory earnings after integration-related items. For Integral Diagnostics (ASX:IDX), cash conversion and the gap between statutory and operating profit remain useful indicators when evaluating the expanded group. Revenue growth alone does not establish how much earnings improvement will ultimately reach shareholders after financing, tax and restructuring costs.

Clinic developments and balance sheet

During 2026, the company announced a new Sunshine Coast Radiology clinic at Maroochy Private Hospital and highlighted additional openings in Wangaratta and Adelaide. Such facilities extend access to imaging services but also require equipment, specialist staffing and reliable referral demand. Integral Diagnostics (ASX:IDX) disclosed net debt equivalent to 2.3 times operating EBITDA at 30 June 2026, compared with 2.6 times a year earlier. This ratio reflects improvement in Leverage but does not remove financing exposure.

An enlarged clinic footprint brings integration tasks around booking systems, imaging infrastructure, reporting workflows and recruitment. Capacity additions may take time to reach mature utilisation levels. The 2026 openings therefore provide operating milestones rather than a guarantee of future earnings. Management execution across the combined network remains an important consideration for Integral Diagnostics (ASX:IDX).

Risks and factors to monitor

The principal Business risks include recruiting and retaining radiologists and imaging specialists, managing wage and equipment costs, maintaining clinical quality and integrating acquired operations. Changes in medical reimbursement arrangements and utilisation patterns can affect revenue per examination. Interest expense and Capital spending also influence the translation of EBITDA into free cash flow. For Integral Diagnostics (ASX:IDX), a more extensive network increases both the opportunities for shared infrastructure and the complexity of delivering consistent service.

Future reporting can be assessed against operating margins, statutory profitability, net debt, imaging Demand and the financial contribution of newly opened sites. These indicators are directly relevant to whether the group can sustain its FY26 operating improvement.

The 2026 results also need to be understood in the context of a larger consolidated group. When acquired clinics contribute for more of a reporting period, reported revenue comparisons can differ from trends at established sites. Identifying organic activity, integration expenditure and the contributions of newer clinics helps distinguish network expansion from underlying demand. This matters for analysing how the additional scale translates into sustained margins and cash generation.

Key Insights

The 2026 disclosures show that Integral Diagnostics Limited (ASX:IDX) must be evaluated through operating performance, financing and execution together. Its business-specific developments create measurable reporting milestones, while published results describe actual outcomes rather than guaranteed future progress. The next financial updates will clarify how operations and cash requirements evolve.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.